CRBU Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Caribou Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$8.33 |
| 52 Week Low | US$1.50 |
| Beta | 2.27 |
| 1 Month Change | -26.48% |
| 3 Month Change | -12.02% |
| 1 Year Change | -71.90% |
| 3 Year Change | -89.49% |
| 5 Year Change | n/a |
| Change since IPO | -90.13% |
Recent News & Updates
Recent updates
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 05
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Sep 30Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
Jul 26Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 13Caribou Biosciences: Selling Close To Cash Balance
Apr 26We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate
Oct 26Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
Oct 12Shareholder Returns
| CRBU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.1% | 0.7% | 0.6% |
| 1Y | -71.9% | -3.4% | 23.7% |
Return vs Industry: CRBU underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: CRBU underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| CRBU volatility | |
|---|---|
| CRBU Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRBU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRBU's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 158 | Rachel Haurwitz | cariboubio.com |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
Caribou Biosciences, Inc. Fundamentals Summary
| CRBU fundamental statistics | |
|---|---|
| Market cap | US$151.22m |
| Earnings (TTM) | -US$148.12m |
| Revenue (TTM) | US$11.48m |
12.7x
P/S Ratio-1.0x
P/E RatioIs CRBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBU income statement (TTM) | |
|---|---|
| Revenue | US$11.48m |
| Cost of Revenue | US$130.97m |
| Gross Profit | -US$119.49m |
| Other Expenses | US$28.63m |
| Earnings | -US$148.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | -1,041.33% |
| Net Profit Margin | -1,290.81% |
| Debt/Equity Ratio | 0% |
How did CRBU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:15 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caribou Biosciences, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |